Shire Buys Renal Disease Biotech Fibrotech, Aims Big At Neuroscience
This article was originally published in The Pink Sheet Daily
Executive Summary
The Ireland-based specialty pharma, itself created by acquisition, generated strong top-line revenue growth and higher profits in the first quarter, helped by full consolidation of ViroPharma. Shire also underscored its aim for future innovation by buying renal disease biotech Fibrotech and predicting its neuroscience operations will double sales by 2020.